ADA and migraine disorder: In this integrated analysis of data from five clinical studies of eptinezumab for the preventive treatment of migraine, the overall incidences of treatment-emergent ADA (15.9%) and NAb (6.2%) were slightly higher than other anti-CGRP mAbs indicated as migraine preventives (24); however, the presence of ADA and NAb did not appear to influence treatment efficacy or safety.